Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK’s Research Support And More – ETF Series Solutions PSYK ETF (ARCA:PSYK), Awakn Life Sciences (OTC:AWKNF), Filament Health (OTC:FLHLF), AdvisorShares Psychedelics ETF (ARCA:PSIL), Mydecine Innovations Gr (OTC:MYCOF), Psyence Group (OTC:PSYGF), Clearmind Medicine (NASDAQ:CMND), Revive Therapeutics (OTC:RVVTF)
[ad_1] Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Currently, in the form of a pill,…
Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment – Clearmind Medicine (NASDAQ:CMND)
[ad_1] Psychedelics company Clearmind Medicine Inc. CMND aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for next-generation novel drug candidates, according to…
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials – Psyence Group (OTC:PSYGF), Revive Therapeutics (OTC:RVVTF)
[ad_1] Life sciences biotech Psyence Group Inc. PSYGF has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). The company issued more…
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans – Awakn Life Sciences (OTC:AWKNF)
[ad_1] Psychedelics biotech Awakn Life Sciences Corp. AWKNF shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed: Revenue of $314.827…
FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder – Ehave (OTC:EHVVF)
[ad_1] After a full review of healthcare provider Ehave Inc.‘s EHVVF IND application, the U.S. Food and Drug Administration (FDA) has authorized the company to proceed with a clinical trial…
How Certain Psychedelics Produce Brain And Behavior Changes: UCL Leads New Study – Small Pharma (OTC:DMTTF)
[ad_1] The University College London (UCL) is conducting a new research project called “Understanding Neuroplasticity Induced by Tryptamines (UNITy)” aimed at assessing brain changes and neuroplasticity induced by these kinds…
FDA OKs Ketamine For Treating Organ Transplant Injuries With ‘Orphan Drug’ Status – PharmaTher Holdings (OTC:PHRRF)
[ad_1] The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. PHRRF an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation. Orphan drug…
Psyched: Psychedelic Therapy In The Workplace, UCL’s Brain Imaging Study, COMPASS Trials And More – Compass Pathways (NASDAQ:CMPS), Irwin Naturals (OTC:IWINF)
[ad_1] Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers Psychedelic healthcare insurance plans provider Enthea announced it will launch its services into 40 markets across…
Colorado’s New Psychedelics Regulations: Co-Author Of The Bill Replies To Concerns
[ad_1] Part two of a three-part series. See previous story: Millennials Tipped The Scales In Colorado Voting, And Psychedelics Laws Are In Their Crosshairs Colorado’s approval of a measure decriminalizing the use,…
Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic – Awakn Life Sciences (OTC:AWKNF)
[ad_1] Psychedelics biotech Awakn Life Sciences Corp. AWKNF announced the continuation of its Nordic expansion plans with a new 5-year lease for the opening of a clinic in the center…
California: Local Psychedelics Decriminalization Proposal Moves To City Council’s Desk
[ad_1] The Berkeley Community Health Commission (CHC) has unanimously decided to move a recently rewritten local psychedelics decriminalization project to the city council for consideration. While other changes were introduced during the CHC…
DEA’s New Production Quotas For Marijuana & Psychedelics Research
[ad_1] The DEA has shared its final production quotas for research drugs for 2023 and is now aiming for further manufacturing goals of several psychedelic compounds than the already substantial increases regarding…
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More – Awakn Life Sciences (OTC:AWKNF), Clearmind Medicine Inc. – Common Shares (NASDAQ:CMND)
[ad_1] LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer’s Studies Led By Beckley Foundation Coming Soon The Beckley Foundation and its founder Amanda Feilding announced a new research program with…
Canada: Psychedelics Delegation Will Confront Federal Health Ministers, Toronto Magic Mushrooms Shop
[ad_1] British Colombia-based non-profit TheraPsil together with a group of patients and medical professionals from across Canada are headed to Ottawa to demand top health officials better access to medical psilocybin. The Canadian Controlled Drugs…
Psyched: Musk’s Empathy Tweets, Psychedelics In Congress, Oregon’s Opt-Outs, MAPS’ MDMA Trial And More – Biomind Labs (OTC:BMNDF), Algernon Pharmaceuticals (OTC:AGNPF)
[ad_1] Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy Elon Musk continues touting the benefits of psychedelics, from his live interview at CodeCon2021 to his most recent…
Psychedelics And Treatment-Resistant Depression: Reactions To COMPASS’ Published Results – Compass Pathways (NASDAQ:CMPS)
[ad_1] (Part two of a four-part series) See previous story in this series: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes COMPASS CMPS’ Phase 2 trial published results…
MAPS Completes Second Phase 3 Trial Of MDMA-Assisted Therapy For PTSD, Topline Data & New Drug Application Next
[ad_1] MAPS Public Benefit Corporation (PBC) announced the final participant’s last Evaluation and Exit Planning therapeutic session was completed in MAPP2, a multi-site Phase 3 study of MDMA-assisted therapy for the…
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes – Compass Pathways (NASDAQ:CMPS)
[ad_1] (Part one of a four-part series) Results from COMPASS Pathways CMPS’ Phase 2b trial assessing the safety of different doses of proprietary synthetic psilocybin paired with psychotherapy for Treatment-Resistant…
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon – Algernon Pharmaceuticals (OTC:AGNPF)
[ad_1] Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. AGNPF has begun screening subjects for its Phase 1 clinical study on the IV formulation of its DMT compound AP-188 in the Netherlands. …
New Collaboration Will Bring Psychedelic Clinics & Retreats With Vertical Offerings To The U.S. – Revitalist Lifestyle (OTC:RVLWF)
[ad_1] Ketamine-therapy provider Revitalist Lifestyle & Wellness Ltd. RVLWF along with psilocybin biotech company WAKE Network Inc. announced a joint venture partnership to open psychedelic clinics and retreats with vertical offerings and a…
This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split – Clearmind Medicine (OTC:CMNDF)
[ad_1] Psychedelics biotech firm Clearmind Medicine Inc. CMNDF CMND has announced the pricing of its underwritten public offering of 1,153,847 common shares at a public price of $6.50 per share,…
Mydecine’s Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months – Mydecine Innovations Gr (OTC:MYCOF)
[ad_1] Mydecine Innovations Group MYCOF, the psychedelics biotech company headquartered in Denver, Colorado with international offices in the Netherlands, reported its financial results and business highlights for the three and nine…
Is Illinois Next Up To Decriminalize Psychedelics? Lawmaker Introduces New Bill
[ad_1] The psychedelics reform wave has arrived in Illinois, specifically Evanston where councilmember Devon Reid intends to advance a local decriminalization measure in an upcoming December 2022 committee meeting, reported Marijuana Moment. Reid’s bill recycles language…
Reunion Neuroscience Presents Q2 2023 Financial Results & Pipeline Update – Reunion Neuroscience (NASDAQ:REUN)
[ad_1] Psychedelics biopharma company Reunion Neuroscience Inc. REUN reported its business update and fiscal results for the second quarter ended September 30, 2022. Reunion’s president and CEO Greg Mayes stated…
MindMed’s Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials – Mind Medicine (NASDAQ:MNMD)
[ad_1] Clinical-stage biotech company Mind Medicine (MindMed) Inc. MNMD reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022. For the period,…